Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Glucotrack, Inc.

OTC: GCTK · Industrial Applications and Services · 11 alerts · CIK 1506983

Share price
$0.1900Close, Nov 16
Market cap
$2.01M
Shares outstanding
10.58MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Glucotrack, Inc. filings on SEC EDGAR ↗

5:01 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Glucotrack Nasdaq/NYSE Compliance Notice

Glucotrack received notice from a Nasdaq Hearings Panel that its securities will be delisted after failing to maintain a $1.00 minimum bid price through the required exception period. Trading on Nasdaq will be suspended on October 30, 2026, and the company plans to transition its common stock to the OTC Markets Group (OTCID).

Counterparty
The Nasdaq Stock Market LLC
4:06 PM ET 8-K
Reverse Stock Split

Glucotrack Reverse Stock Split

Glucotrack, Inc. implemented a 1-for-2 reverse stock split of its common stock effective October 23, 2026. The split reduced the number of outstanding shares from approximately 2.37 million to 1.18 million to satisfy Nasdaq listing requirements. The company's common stock began trading on a split-adjusted basis on October 26, 2026.

5:30 PM ET 8-K
Reverse Stock Split

Glucotrack Reverse Stock Split

Glucotrack, Inc. announced a 1-for-2 reverse stock split of its common stock effective October 26, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split will reduce the outstanding share count from approximately 2.37 million to 1.18 million shares. Separately, the company raised $2.0 million in gross proceeds through the issuance of senior secured convertible promissory notes and warrants.

4:05 PM ET 8-K
Other 8-K Filing

Glucotrack Other 8-K Filing

Glucotrack entered into a waiver agreement with warrant holders to terminate certain restrictive covenants and exercise price adjustment provisions from a July 2026 purchase agreement. In consideration for these waivers, the company agreed to issue new warrants to purchase 406,198 shares of common stock at an exercise price of $7.50 per share.

4:45 PM ET 8-K/A
M&A Deal

Glucotrack M&A Deal with Lokahi Therapeutics Inc.

Glucotrack, Inc. filed an amended 8-K to provide updated pro forma financial statements regarding its completed acquisition of Lokahi Therapeutics Inc. The update specifically reflects the impact of a 1-for-15 reverse stock split that became effective on August 28, 2026. Following the merger, Lokahi became a direct wholly owned subsidiary of Glucotrack.

Counterparty
Lokahi Therapeutics Inc.
5:33 PM ET 8-K
Loan & Debt

Glucotrack Debt Financing Update with September Investors

Glucotrack, Inc. entered into amendments for its senior secured convertible promissory notes and various common stock purchase warrants issued in July, August, and September 2026. The amendments primarily remove downward adjustments to the Floor Price and mandate that make-whole payments be satisfied only in cash, while the company also confirmed the full repayment of its July Bridge Notes.

Counterparty
September Investors
5:16 PM ET 8-K
Capital Raise

Glucotrack Capital Raise of $3.1M

Glucotrack, Inc. entered into a securities purchase agreement for a registered direct offering of 169,388 shares of common stock and pre-funded warrants for 1,350,220 shares, raising approximately $3.1 million in gross proceeds. The offering was priced at $2.04 per share (or $2.039 per pre-funded warrant) and is intended to fund debt repayment and general working capital.

Value
$3.1M
Counterparty
institutional investors
9:22 AM ET 8-K
Business Update

Glucotrack Business Update

Glucotrack CEO Erik Emerson provided a strategic update following the company's recent business combination with Lōkahi Therapeutics. The update highlights the development of LT-100 for osteoarthritis knee pain, including the submission of a clinical protocol for regulatory review and plans for a study evaluating subcutaneous injection efficacy.

5:11 PM ET 8-K
Leadership Change

Glucotrack Leadership Change

Paul V. Goode resigned from the Board of Directors of Glucotrack, Inc. effective September 14, 2026. Mr. Goode cited a potential conflict of interest between the company and its subsidiary regarding the implementation of duties and rights under a prior merger agreement with Lokahi Therapeutics, Inc.

Counterparty
Paul V. Goode
4:16 PM ET 8-K
Shareholder Meeting

Glucotrack Shareholder Meeting

Glucotrack held a special meeting of stockholders on September 11, 2026, where shareholders approved the full issuance of common stock related to an equity line of credit with White Lion Capital and senior secured convertible promissory notes. Additionally, the company amended a securities purchase agreement with a PIPE purchaser to ensure warrant exercises comply with Nasdaq Listing Rule 5635(d) following stockholder approval.

9:09 AM ET 8-K
Loan & Debt

Glucotrack $11.6M Debt Financing with certain investors

Glucotrack, Inc. issued senior secured convertible promissory notes in the aggregate principal amount of approximately $11.6 million, which includes a 22% original issue discount. The financing involved $4.5 million in new cash proceeds and the exchange of $4.5 million in existing notes, with the new notes bearing 8% interest and maturing in June 2027.

Value
$11.6M
Counterparty
certain investors
Term
9 months

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.